The sales of Terapia Ranbaxy, part of the Indian Ranbaxy group, fell 14% in the first half of this year, compared with the corresponding period in 2007, and reached 57 million dollars (more than 36 million euros) as a result of the impact and reforms in the health care field on the pharmaceuticals market, according to the half-year report of the Indian group. After having posted 29% sales decline in the first quarter of this year, to 26 million dollars (more than 16 million euros), Terapia Ranbaxy saw sales reach 31 million dollars and an increase of 5% on April-June 2007. Compared with the first quarter, the sales in the April-June period grew by 17% and revealed a gradual improvement of operations and the positive impact of the introduction of a new drug prescription method, by brand, starting from April 1, according to the information in the report.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
